EFPIA - NEWSLETTER

EFPIA Newsletter 13 February 2025

Regulatory innovation can unlock pharma competitiveness

Read the full article by Nathalie Moll, Director General, EFPIA

By embracing the agility and efficiency adopted during the pandemic, the EU can become a life sciences leader again.

Thirty years after the EMA was established to accelerate patient access to innovative medicines, there is much to be proud of, including a record number of assessments in 2024.

Building on this strong foundation, the EU can reverse the negative trends we are facing in terms of falling R&D investment and clinical trials, and continue to attract the best innovations for our patients.

Health and the life sciences sector must be a strategic pillar of the next EU long-term budget

For Europe to remain relevant and competitive in a turbulent world, it needs to invest in the wellbeing of its citizens. Making health and the life sciences sector a central pillar of the next Multi-Annual Financial Framework (MFF), starting in 2028, would send a strong signal.

Read the EU Health Coalition's 9 recommendations for strengthening health through the MFF.

Towards better cardiovascular health in Poland - Read the full report

In Poland, cardiovascular healthcare is one of the key challenges for the healthcare system, with cardiovascular disease (CVD) among the leading causes of death and hospitalisation. As the number of CVD cases grows, it is essential to secure not only adequate financial resources but also to introduce population-level interventions and structural changes that enhance the effectiveness of care across all levels of the healthcare system.

Read the full report here.

Events

25 FEB 2025

The case for investing in a healthier future for the European Union Online

An overview of the economic and health benefits of investing in the prevention, early detection and treatment of five...

Learn more →

19 MAR 2025

Cancer Care 2030: From policy ambition to impact Brussels, Belgium

Join us on 19 March in Brussels to discuss how we can work together to accelerate progress to improve cancer care

Learn more →

2024 Pipeline Review: Cardiovascular disease (CVD)

Elevated lipoprotein (a) levels are a risk factor for cardiovascular disease. New therapies can reduce the amount of lipoprotein (a) and reduce its associated risks.

Imagine how many strokes and heart attacks could be prevented.

Discover more in our pipeline review.

What we are reading

Belgium’s new government unveils wide-ranging health reform agenda, including key pharma measures... 05 February 2025 (Euractiv)

Competition of regulatory ecosystems in approving medicines: policy implications in the case... 05 February 2025 (ScienceDirect)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶